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Hypercholesterolemia diets are considered as majorsources to cause cardiac hypertrophy. This study intends to evaluate the eﬀects
of Li-Fu formula on cardiac hypertrophy induced by hypercholesterolemia diet. Twenty-four male Golden Syrian hamsters were
randomly divided into control, cholesterol and Li-Fu formula groups and fed with diﬀerent experimental diets for 2 months.
Histopathological analysis and western blotting were performed to measure the myocardial architecture, and various cardiac
hypertrophy-associated molecules in the excised left ventricle from hamsters. The ratios of whole heart weight/body weight (BW)
and left ventricle weight/BW were signiﬁcantly higher in the cholesterol group but signiﬁcantly lower in the Li-Fu formula group.
The protein levels of both atrial natriuretic peptide and brain natriuretic peptide were signiﬁcantly increased in the cholesterol
group but signiﬁcantly reduced in the Li-Fu formula group. Additionally, signiﬁcantly increased interleukin-6, STAT3, MEK5, p-
ERK5 and non-cardiomyocyte proliferate signal molecules such as p-MEK and p-ERK, were detected in the cholesterol group but
signiﬁcantlyreduced intheLi-Fuformulagroup.Notably,nosigniﬁcantvariationsofinﬂammatorysignalingmolecules,including
p-P38 and p-JNK, were detected in all groups. Our experimental results demonstrated the signiﬁcant reductions of cardiac
hypertrophy and related eccentric hypertrophy signaling, non-cardiomyocyte proliferate signaling in the excised left ventricle of
hamsters from the Li-Fu formula. We suggested the protective eﬀects of Li-Fu formula on cardiac hypertrophy that may be useful
in prevention or treatment of hypertrophy-associated cardiovascular diseases.
1.Introduction
Hypercholesterol diets are the major cause of cardiac hyper-
trophy [1]. Cardiac hypertrophy is recognized as a cardiac
adaptive response to any stress that can exist in a state of
compensation or progress to a decompensated state over
time [2]. Prolonged hypertrophy of the cardiomyocytes is
demonstrated as the main cause of sudden cardiac death2 Evidence-Based Complementary and Alternative Medicine
[3]. A number of studies indicated that various diseases have
beenassociated withcardiachypertrophy includingocclusive
atherosclerotic coronary heart disease (CHD), associated
myocardial infarction (MI), heart failure hypertension,
endocrine disorders, toxicants and bacterial endocarditis [4–
7].
Atrial natriuretic peptide (ANP) and brain natriuretic
peptide(BNP)are known asthecardiac hormonesin normal
adults that were secreted by the atria and ventricles. Higher
levels of ANP and BNP expression are expressed in the
fetal ventricles than adult ventricles [8]. Cardiac ANP and
BNP levels are increased in MI of animal models [9], heart
failure [10], hypertrophy [11] and also in human cardiac
diseases [12]. Increased expressions of ANP and BNP are
observed in ventricular during the molecular process of
cardiac hypertrophy, which are recognized as markers of the
induction of the embryonic gene program in ventricular
hypertrophy [13].
Interleukin (IL)-6 is known as a potent hypertrophic
factor of cardiomyocytes [14, 15]. The IL-6 receptor
system consists of various signaling pathways including
inﬂammatory-related p38 MAPK, hypertrophy involved
STAT1-STAT3 heterodimer pathway, STAT3 homodimer
pathway and non-cardiomyocyte proliferative related MAPK
extracellular signal-regulated kinase (ERK)s pathway that
are activated by the dimerization of gp130 [16–19]. The
activation of STAT3-dependent signaling pathway by gp130
was reported to promote cardiac myocyte hypertrophy
[20], herein the STAT1 and the STAT3 were shown to
be chronically phosphorylated in the failing heart [21].
Moreover, the ERK5 molecule plays a critical role in post-
natal eccentric hypertrophy of the heart [9, 22]. ERK5 and
its upstream MAPK-kinase 5 (MEK5) reveals a speciﬁc
role in transduction of cytokine signals that regulate serial
sarcomere assembly and in the induction ofeccentric cardiac
hypertrophy resulting indilatedcardiomyopathyand sudden
death [22]. Therefore, it is crucial to investigate the patho-
logic role of IL-6-MEK5-ERK5 signaling pathway under
cardiac hypertrophy. Additionally, various molecules have
been elucidated responsible for the development of cardiac
hypertrophy, including mitogen activated protein kinase
(MAPK), phosphoinositide 3-kinase (PI3K) and calcineurin
pathway [23]. The extracellular-regulated kinase (ERK), the
c-Jun N-terminal kinases (JNK)and the p38 MAPK cascades
(p38) enrolled in the MAPK pathway also play crucial roles
in the development of cardiac hypertrophy [24].
To avoid the side eﬀects by administration of western
drugs, growing studies were performed to investigate the
natural products for cardiac protection that have been used
asdrugs ordiet supplementsfora long history inmany med-
icalexperiences. Recentstudiesreported thecardioprotective
eﬀectofvariousorientalherbextractsordietarysupplements
including Fructus crataegi, Salvia miltiorrhiza and Astragali
radix. The quercetin is the main ingredient in Fructus
crataegi that has been demonstrated as an anti-inﬂammatory
substance by inhibiting TNF-α release from macrophages
and recognized to have cardiac protective eﬀect [25, 26].
Salviamiltiorrhizaismainlycomposedofsodiumtanshinone
IIA sulfonate (STS), a derivative of tanshinone IIA that
can reduce myocardial infarct size and prolong the survival
c a r d i a cc e l li nr a b b i ta n dh u m a n[ 15, 27, 28]. Astragali
radix contains many isoﬂavones, isoﬂavonoids and many
saponins, which have been demonstrated to have protective
eﬀects on heart by reducing inﬂammation, oxidant and
cardiac ischemia-reperfusion injury [29–34]I no u rr e c e n t
publication, we also demonstrated the protective eﬀect of Li-
Fu formula composing of celery, black fungus, mushroom,
Saliva miltior rhiza, Crataegi cuneata and Astragali radix on
cardiac apoptosis [35].
To further understand the eﬀects and possible mecha-
nismsofLi-Fuformulaoncardiachypertrophy,weexamined
the expression of hyper-trophic associated molecules in the
cardiactissuesfromhamsters thatwerefedwithhypercholes-
terol diets and suggested the cardiac protective eﬀects of Li-
Fu formula by reducing the cardiac hypertrophy.
2.Methods
2.1. Animals and Diet. Male Golden Syrian hamsters weight-
ing 135–170g at the age of 8 weeks were purchased from
National Laboratory Animal Center, Taipei, Taiwan, and
housed in an animal room at 22 ± 2◦C with a 12/12h light-
dark cycle under supervision of Institutional Animal Care
and Use Committee of China Medical University, Taichung,
Taiwan. Hamsters were acclimatized for 2 weeks while
receiving free access to water and were fed chow diet (Lab
Diet 5001; PMI Nutrition International Inc., Brentwood,
MO, USA) ad libitum.F o re a c he x p e r i m e n t ,2 4h a m s t e r s
were randomized into three groups as control, cholesterol
and Li-Fu formula groups and switched to experimental
diets. Three independent experiments were performed. The
control, cholesterol and Li-Fu formula groups received chow
diet, chow diet with 0.2% cholesterol (Sigma, St Louis, MO,
USA), and chow diet with 0.2% cholesterol and 2% Li-Fu
formula for 8 weeks, respectively. Celery and Black fungus
were obtained from common supermarket and mushroom,
Saliva miltior rhiza, Crataegi cuneata and Stragali radix were
purchased from traditional Chinese pharmacy. To make Li-
Fu formula, every component of desired weight was crushed
and mixed with a blender, then placed in 1000ml distilled
water and boiled for 1h under reﬂux. The resultant solution
was divided into several parts and stored in a –80◦C freezer
for further use [35]. The Li-Fu formula is composed of
celery,blackfungus,mushroom,Salivamiltiorrhiza,Crataegi
cuneata and Astragali radix as shown in Table 1 and the
experimental dietary composition is shown in Table 2.D i e t s
were prepared weekly and stored at −80◦C. All experimental
procedures were performed according to the NIH Guide
for the Care and Use of Laboratory Animals. All protocols
were approved by the Institutional Animal Care and Use
Committee of China Medical University, Taichung, Taiwan.
Food intake and food spillage were measured daily, and body
weight was recorded every 3 days.
2.2. Cardiac Characteristics. Three groups of hamsters at age
of 8-9 months were weighed and decapitated after receiving
8 weeks of experimental diets. The hearts of animals wereEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Cardiac cross sections and cardiomyopathic changes in hamsters of control, cholesterol and Li-Fu formula groups. (a) The cross
section of whole heart in the three groups. Arrows indicate that the left ventricular lumen diameters increased in the cholesterol group but
decreased in the Li-Fu formula group. (b) Representative histopathological analysis of cardiac tissue sections with hematoxylin and eosin
staining in hamsters of control, cholesterol and Li-Fu formula groups. The images of myocardial architecture were magniﬁed by 100 times.
Table 1: Composition of Li-Fu formula.
Items Weight (g) Portion (%)
Celery(a) 25 2.5
Black fungus(b) 320 32.3
Mushroom(c) 420 42.4
Saliva miltior rhiza 75 7.6
Crataegi cuneata 75 7.6
Stragali radix 75 7.6
(a)Celery is also kanown as Apium graveolens.
(b)Blackfungus indicatesWood ear, or pinyin: m` uˇ er, lit.“wood ear” or “tree
ear” are commonly sold in Asian markets as dietary supplement.
(c)The standard for the name “mushroom” is the cultivated white button
mushroom, Agaricus bisporus.
Table 2: Formulation and calculated composition of diets.
Ingredients (%
wt/wt) Control diet Cholesterol
diet
Experimental
diet
Chow diet,
99.5 99.3 97.3 (Rodent 5001)
Soybean oil 0.5 0.5 0.5
Cholesterol 0 0.2 0.2
L i - F u f o r m u l a 002
excised and cleaned with distilled H2O. The left and right
atrium and ventricle were separated and weighed. The BW,
left ventricle weight (LVW), the ratios of the whole heart
weight(WHW)toBWandtheratiosoftheLVW toBW,were
measured and calculated.
2.3. Hematoxylin-Eosin Staining. The hearts of animals were
excised and were soaked in formalin and covered with wax.
Slides were prepared by deparaﬃnization and dehydration.
They were passed through a series of graded alcohols (100,
95 and 75%), 15min each. The slides were then dyed with
hematoxylin. After gently rinsing with water, each slide was
then soaked with 85% alcohol, 100% alcohol I and II for
15min each. At the end, they were soaked with Xylene I
and Xylene II. Photomicrographs were obtained using Zeiss
Axiophot microscopes.
2.4. Tissue Extraction. Cardiac tissue extracts were obtained
by homogenizing the left ventricle samples in a PBS
buﬀer (0.14MNaCl, 3mMKCl, 1.4mMKH2PO4,1 4m M
K2HPO4) at a ratio of 100mg tissue/0.5ml PBS for 5min.
The homogenates were placed on ice for 10min and then
centrifuged at 12000g for 30min. The supernatant was
collected and stored at –70◦C for further experiments.
Protein concentration was determined using a BioRad
Protein Assay (BioRad Laboratories, Hercules, CA, USA)
and were quantiﬁed by absorbance at 595 nm using a
spectrophotometer (Beckman Coulter, Palo Alto, CA, USA).
2.5. Western Blot. Western blotting was performed as
described in our previous report [35]. Protein samples were
separated in 12.5% of SDS-PAGE and electrophoretically4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: (a) The representative protein products of ANP and
BNP extracted from the left ventricles of excised hearts in hamsters
of control, cholesterol and Li-Fu formula groups were measured
by western blotting analysis. ((b), (c)) Bars represent the relative
protein quantiﬁcation of ANP and BNP on the basis of α-tubulin.
All bars indicate mean values ± SD (n = 6i ne a c hg r o u p ) .∗∗P<
.01, signiﬁcant diﬀerences between control and cholesterol group.
#P<. 05 and ##P<. 01, signiﬁcant diﬀerences between cholesterol
and Li-Fu formula groups.
transferred to nitrocellulose membrane (Amersham Bio-
sciences, Piscataway, NJ). After blocking with 5% non-fat
dry milk in PBS for 30min at room temperature, antibodies
against ANP, BNP, IL-6, STAT3, MEK5, p-EKR5, MEK, p-
MEK, phosphorylated ERK (p-ERK), p-P38, JNK, p-JNK
and α-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were diluted to 1:500 with 5% nonfat dry milk in
PBS and then incubated for 1.5h at room temperature. The
Table 3: WHW, LVW, WHW to BW, and LVW to BW ratio.
Control Cholesterol Li-Fu formula
Whole heart weight
(mg) 410.6 ± 36.10 423.1 ± 21.92 377.1 ± 2.40
LVW (mg) 290.5 ± 8.82 292.0 ± 12.98 269.1 ± 10.10
WHW/BW(a) 3.8 ± 0.03 3.9 ± 0.01∗ 3.6 ± 0.03#
LVW/BW(a) 2.7 ± 0.04 2.8 ± 0.01∗ 2.6 ± 0.03#
(a)Data present in percentage.
∗P < .05, versus control.
#P < .05, versus cholesterol.
membranes were washed twice with PBS-Tween for 1h and
incubatedwithsecondantibodyconjugatedwithhorseradish
peroxidase (Promega Corp., Madison, WI, USA) for 1h that
was diluted 1000-fold with 5% nonfat dry milk in PBS.
Pierce’s Supersignal West Dura HRP Detection Kit (Pierce
BiotechnologyInc.,Rockford,IL)wasusedtodetectantigen-
antibody complexes. The blots were scanned and quantiﬁed
by densitometry (Appraise, Beckman-Coulter, Brea, CA,
USA).
2.6. Statistical Analysis. All of the statistical analyses were
performed using SPSS10.0software (SPSSInc.,Chicago,IL).
Three independent experiments were repeated. Statistical
analyses were performed using the analysis of variance plus
posterior multiple comparison test to test the diﬀerence. The
databetweentwoexperimental animal groupswascompared
by Student’s t-test for two independent samples. In all cases,
ad i ﬀerence at P<. 05 was considered statistically signiﬁcant.
3.Results
3.1.Experimental DietsandCardiacCharacteristics. To inves-
tigate the eﬀect of Li-Fu formula on hypertrophy in cardiac
cells, we examined the BW and cardiac characteristics.
First, Li-Fu formula was prepared as described in materials
and methods and the compositions of the Li-Fu formula
was shown in Table 1. Table 2 presents the ingredients of
experimental diets for diﬀerent groups of hamsters. BW,
LVW, the ratios of WHW to BW and the ratios of LVW to
BW of hamsters from control, cholesterol and Li-Fu formula
groups were detected (Table 3). The ratios of WHW/BW
and LVW/BW were signiﬁcantly higher in hamsters of
cholesterol group compared to control group. Notably, the
ratios WHW/BW and LVW/BW were signiﬁcantly reduced
in the hamsters from Li-Fu formula group compared with
cholesterol group (Table 3).
3.2. Cardiac Architecture Changes. To further conﬁrm
the eﬀect of Li-Fu formula on cardiac hypertrophy, we
performed cross-sectional analysis of whole heart and
histopathological analysis of ventricular tissue stained with
hematoxylin and eosin. We found that ventricular wall
thickness signiﬁcantly increased in the cholesterol group,
but decreased signiﬁcantly in the Li-Fu formula group
(Figure 1(a)). The ventricular myocardium in control group
showed normal architecture with normal interstitial space.Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: (a) The representative protein products of IL-6, STAT3, MEK5 and p-ERK5 extracted from the left ventricles of excised hearts in
hamsters of control, cholesterol and Li-Fu formula groups were measured by western blotting analysis. ((b)–(e)) Bars represent the relative
protein quantiﬁcation of IL-6, STAT3, MEK5 and p-ERK5 on the basis of α-tubulin. All bars indicate mean values ± SD (n = 6i ne a c h
group). ∗∗P<. 01, signiﬁcant diﬀerences between control and cholesterol groups. ##P<. 01, signiﬁcant diﬀerences between cholesterol and
Li-Fu formula groups.
In contrast, the irregular myocardial architecture and the
increased interstitial space were observed in cholesterol
group that showed structural disorganization and cardiomy-
ocyte disarray. However, these abnormal architectures were
signiﬁcantly decreased in Li-Fu formula group compared
with cholesterol group (Figure 1(b)). Moreover, the protein
levels of both ANP and BNP were signiﬁcantly increased
in hearts of cholesterol group compared to control group.6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: (a) The representative protein products of p-MEK and
MEK extracted from the left ventricles of excised hearts in hamsters
of control, cholesterol and Li-Fu formula groups were measured
by western blotting analysis. ((b), (c)) Bars represent the relative
protein quantiﬁcation of p-MEK and MEK on the basis of α-
tubulin. All bars indicate mean values ± SD (n = 6i ne a c hg r o u p ) .
∗∗P<. 01, signiﬁcant diﬀerences between control and cholesterol
groups. ##P<. 01, signiﬁcant diﬀerences between cholesterol and
Li-Fu formula groups.
In contrast, signiﬁcantly reduced ANP and BNP protein
expressions were detected in hearts of hamsters from Li-Fu
formula group (Figure 2).
3.3. Eﬀect of Li-Fu Formula on Cardiac Hypertrophy-
AssociatedSignaling Pathways. Inordertoidentifythehyper-
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Figure 5: (a) The representative protein product of p-EKR
extracted from the left ventricles of excised hearts in hamsters of
control, cholesterol and Li-Fu formula groups were measured by
western blotting analysis. (b) Bars represent the relative protein
quantiﬁcation of p-ERK on the basis of α-tubulin. All bars indicate
mean values ± SD (n = 6i ne a c hg r o u p ) .∗∗P<. 01, signiﬁcant
diﬀerences between control and cholesterol groups. ##P<. 01,
signiﬁcant diﬀerences between cholesterol and Li-Fu formula
groups.
trophic factor IL-6, signal transducer and activator of tran-
scription STAT-3 and mitogen-activated protein kinase/ERK
(MEK) signaling pathways that were associated with the
cardiac hypertrophy induced by hypercholesterol diet, the
protein products of IL-6, STAT3, MEK5 and p-ERK5 were
measured by western blotting. In hearts from the cholesterol
group, the protein products of IL-6, STAT3, MEK5 and p-
ERK5 were signiﬁcantly increased compared to the hearts
of control group (Figure 3). However, signiﬁcantly decreased
IL-6, STAT3, MEK5 and p-ERK5 protein expression was
observed in hearts of Li-Fu formula group (Figure 3). We
further detected the protein levels of MEK and p-MEK. As
shown in Figure 4, signiﬁcantly increased MEK and p-MEK
protein levels were detected in hearts of cholesterol group
compared to control group (Figure 4). Notably, signiﬁcantly
decreased p-MEK was observed in hearts of Li-Fu formula
group compared to cholesterol group (Figure 4). Addition-
ally, signiﬁcantly increased p-ERK protein was detected in
hearts of cholesterol group compared to control group. In
contrast, signiﬁcantly reduced p-ERK protein was observed
in hearts of hamsters from Li-Fu formula group compared
to those from cholesterol group (Figure 5). However, no
signiﬁcant variations in p-P38 and p-JNK protein levels were
detected among all experimental groups (data not shown).Evidence-Based Complementary and Alternative Medicine 7
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Figure 6: Our proposed hypothesis that cardiac IL-6, MEK-5-
ERK-5 and STAT3 hypertrophic pathways and MEK1/2-ERK1/2
non-cardiacmyocyte proliferative pathway are more activated in
hyper cholesterol-fed hamster hearts. The eccentric hypertrophy-
related pathway, IL-6-related MEK5-ERK5 pathways and MEK1/2-
ERK1/2 non-cardiacmyocyte proliferative pathway may play a part
of role for developing eccentric cardiac hypertrophy and patho-
logical changes in hyper cholesterol-fed hamster hearts. Dash lines
represent possible theoretical pathways but are still unconﬁrmed.
Up arrows and down arrows on the right side represent increases
and decreases, respectively.
4.Discussion
Hypercholesterolemia diets have been recognized as the
major cause of cardiac hypertrophy and are associated with
various heart diseases [4, 5, 7, 32]. Our experimental results
indicate the signiﬁcant reduction of the WHW/BW and
LVW/BW ratios in hamsters from Li-Fu formula group
compared with those from cholesterol group. Moreover, the
hypertrophic marker protein such as ANP, BNP, eccentric
hypertrophic-related factors such as IL-6, STAT3, MEK5, p-
ERK5, p-MEK and p-ERK were signiﬁcantly increased in
cholesterol group, whereas signiﬁcant reduction of all these
proteins were observed in Li-Fu formula group.
The interleukin (IL)-6 is known as a pleiotypic factor
that has been associated with various cardiac diseases
[14, 36, 37]. Elevated IL-6 mRNA is observed in patients
of cardiac hypertrophy with hypertrophic cardiomyopathy
[37]. As shown in Figure 6,S T A T 3a n dM A P K( E R K ) s
pathwaywere inducedbyIL-6 receptorsignaling systems and
contributed to the cardiac hypertrophy [1, 9]. Accordingly,
our experimental results revealed signiﬁcant elevation of
IL-6 expression in the excised ventricle of hamsters from
Cholesterol group as well as those hypertrophic related sig-
naling molecules includingSTAT3, MEK5, p-ERK5. Notably,
the signiﬁcant reduction of these hypertrophic factors and
signaling molecules were detected in the excised ventricle of
hamsters from Li-Fu formula group. To further clarify the
involved signaling pathway, we further examined the MAPK
pathway that consists three major cascades including the
non-cardiomyocyte proliferativeERK,and theinﬂammatory
related c-Jun N-terminal kinases (JNK), and the p38 MAPK
cascades (p38) [24]. As revealed in current study, signiﬁcant
increase of p-ERK was observed in the excised ventricle of
hamster from Cholesterol group and the p-ERK level was
signiﬁcantly reduced in the excised ventricle of hamster from
Li-Fu formula group. Moreover, higher increase of p-MEK,
the upstream kinase activator of EKR, was also detected in
hamsters from Li-Fu group compared to cholesterol group.
However, no signiﬁcant diﬀerencesin protein levelsof p-P38
and p-JNK were detected between hamsters from cholesterol
and Li-Fuformulagroups. Althoughthe precisemechanisms
of Li-Fu formula on reducing IL-6 expression merit further
investigations, these ﬁndings indeed demonstrated that Li-
Fu formula has the eﬀect against cardiac hypertrophy by
attenuating non-cardiomyocyte proliferation related p-ERK
cascade but not P38 or JNK cascade.
Because of the moderated side eﬀects than Western
drugs, more than half of the population in the world relies
ontraditional medicinefortherapeuticneeds. Indeed,herbal
remedies and alternative medicines are used throughout
the world and in the past herbs often represented the
original sources of most drugs [38–40]. The Li-Fu for-
mula was ﬁrst created by Dr Li-Fu Chen, China Medical
University, Taichung, Taiwan, and composed of various
dietary supplements and oriental herbs, including celery,
black fungus, mushroom, Saliva miltior rhiza, Crataegi
cuneata and Astragali radix that were routinely used as
traditional medicine in orientalworlds. Forinstance, a major
ingredient of Li-Fu formula, Salvia miltiorrhiza,i sk n o w n
as “Danshen” and mainly composed of sodium tanshinone
IIA sulfonate (STS), a derivative of tanshinone IIA that is
also known to protect cardiovascular ischemia-reperfusion
and oxidant injuries [15, 27, 28, 30, 32–34, 39, 40]. To
elucidatetheeﬀectand possiblemechanism ofLi-Fuformula
on hypercholesterolemia-induced cardiac hypertrophy, we
performed the histopathological analysis and western blot-
ting to measure the myocardial architecture, and expression
of diﬀerent cardiac hypertrophy-associated molecules in
the excised left ventricle from hamsters. Notably, markedly
reduced ratios of WHW/BW and LVW/BW were observed
in hamsters from Li-Fu formula group compared with
those from cholesterol group. These ﬁndings did suggest the
protective eﬀects of Li-Fu formula on cardiac hypertrophy.
In the world, more than half of the population relies
on traditional medicine for therapeutic needs either by
stewing or solution extracting [39–41]. Although the precise
mechanism of most herbal medicine or dietary supplement
has not been fully understood, the experience of the
traditionaluseovertheyearscannotbeneglected.Altogether,
our experimental results revealed that Li-Fu formula, the
traditional orientalherbsand diet supplementsformulahave8 Evidence-Based Complementary and Alternative Medicine
signiﬁcant protective eﬀects against cardiac hypertrophy.
Besidestheattenuated expression ofANPand BNP,theeﬀect
against cardiac hypertrophy of Li-Fu formula is probably via
the reduction of eccentric hypertrophy related IL-6 receptor
pathway and non-cardiomyocyte proliferation involved ERK
signaling cascade but not JNK and P38 cascades.
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